| 形态 | Liquid |
|---|
| 宿主种属 | Humanized |
|---|
| 克隆性 | Monoclonal |
|---|
| 抗体亚型 | VH-VH |
|---|
| 纯度 | >95% purity as determined by SDS-PAGE. |
|---|
| 纯化方式 | Protein A/G purified from cell culture supernatant. |
|---|
| 浓度 | 1.6mg/ml |
|---|
| 内毒素水平 | Please contact the lab for this information. |
|---|
| 应用 | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| 种属反应性 | Human |
|---|
| 靶标 | von Willebrand antigen II, von Willebrand factor, F8VWF, vWF, VWF |
|---|
| 储存缓冲液 | 20 mM citric acid, 6.2% sucrose, 0.01% Tween80 |
|---|
| 稳定性和储存 | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
|---|
| 表达系统 | Mammalian Cells |
|---|
| 登录号 | P04275 |
|---|
| 背景信息 | Caplacizumab (ALX-0681) is a humanized anti-von Willebrand factor (vWF) nanobody. Caplacizumab inhibits the vWF-mediated platelet adhesion and prevents further microthrombi formation. Caplacizumab can be used for the research of thrombotic thrombocytopenic purpura (TTP).<br> |
|---|
| 别名 | ALX-0081, PMP12A2h1-linkerAAA-PMP12A2h1, caplacizumab-yhdp, 915810-67-2 |
|---|
| 备注 | For research use only. Not suitable for clinical or therapeutic use. |
|---|